Crisaborole 2%
Sponsors
Innovaderm Research Inc., Pfizer, Boston University, Shalamar Institute of Health Sciences
Conditions
Atopic DermatitisAtopic Dermatitis (AD)Dermatitis, Atopic
Phase 3
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
CompletedNCT04040192
Start: 2019-09-12End: 2022-01-19Updated: 2023-03-08
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
TerminatedNCT04498403
Start: 2020-09-14End: 2020-12-18Updated: 2021-08-12
Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis
Not yet recruitingNCT07162896
Start: 2026-06-30End: 2027-06-30Target: 66Updated: 2025-09-09
Phase 4
Different Application Rates of Crisaborole Ointment 2% in Adults With Mild to Moderate Atopic Dermatitis
CompletedNCT03868098
Start: 2019-05-21End: 2020-11-25Updated: 2021-08-24
Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis
TerminatedNCT05200403
Start: 2022-07-26End: 2024-02-15Updated: 2025-03-14